Trinity buys Verix to turn pharma AI insights into field action
What's the deal? Trinity Life SciencesDealroom has a profile for this one. Try Dealroom → has acquired Verix, the pharma-native commercial intelligence company behind the patented, AI-powered Tovana platform, for undisclosed terms. Verix's full team joins Trinity, adding an AI execution layer to its TrinityEDGE commercialization platform.
What do they do? Trinity integrates human and AI expertise for life sciences commercialization. Tovana turns prescription, claims, clinical, and engagement data into next-best-action, dynamic targeting, and omnichannel orchestration for brand, field, and digital teams.
Why now? Pharma has bought AI but not the payoff. Trinity's 2025 benchmark found 100% of surveyed organizations had adopted generative AI, yet only 10% of commercial strategy leaders had a clear AI strategy they were scaling.
What's the endgame? Trinity wants to close the gap between insight and action — the moment targeting lists go stale and reps ignore recommendations they don't trust. Combining Tovana with TrinityEDGE aims to move the company from telling clients what they know to what they do next.
Tovana is not a new build: it has run in live pharma and biotech deployments since 2007. One of the largest US pharmaceutical oncology divisions increased new prescriptions by 15 to 25% with the platform, and a rare oncology team improved field-facing NPS 12-fold.
What's the catch? Terms were not disclosed, and joint offerings are expected only in the first half of 2027, so the practical impact will hinge on integration and customer adoption.
The Verix deal deepens Trinity's technology capabilities, building on its 2025 acquisition of EVERSANA's APACME advisory business, which expanded geographic reach. Over three years, Trinity has layered software, data, and AI onto its advisory services, growing to 1,500 professionals across 14 offices on five continents.
The signal: The deal fits a wider push to pair AI-driven commercial analytics with execution. In April, rival Axtria acquired Conexus SolutionsDealroom has a profile for this one. Try Dealroom → to link its AI platform with CRM implementation, while Veeva's reported acquisition of Ostro added AI-enabled engagement — a sign that life sciences buyers want strategy-to-field-execution under one roof.
Read more: prnewswire.com
Image credit: Generated with Gemini
